- advertisement -

Sheffield attracts ?2m grant -REPOSE trial: pump/DAFNE

Discussion in 'UK' started by Ellen, Oct 27, 2011.

  1. Ellen

    Ellen Senior Member

    Joined:
    Oct 22, 2005
    Messages:
    8,240
    Sheffield attracts ?2m grant to help diabetes sufferers

    A clinical trial being led in Sheffield has attracted ?2m in funding to assess a new approach to care for diabetes patients.

    The trial, called REPOSE, is to analyse how effective insulin pumps, in combination with an education course called DAFNE, can be in treating patients with type-1 diabetes when compared with the more standard treatment of injections with education.

    Funded by the government-run NHS Health Technology Assessment Programme, the trial is being carried out by Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield in partnership with six other hospital centres around the country.

    The chief investigator for the trial is Simon Heller (pictured), Professor of Clinical Diabetes at the University of Sheffield and Consultant Diabetologist at Sheffield Teaching Hospitals. He said: ?This is fantastic news for Sheffield and is very promising for diabetes patients.

    ?Insulin pumps are used widely elsewhere but relatively rarely in the UK, despite some promising signs that they are effective in some people. This study will allow us to assess quite how effective they are for patients who have been taught to self-care.

    ?It is important that patients are able to look after their own care as much as possible, but we need to know which treatment is likely to lead to be more effective when we train them to do this. The study will make a vital contribution in this respect.?

    A total of 280 adults (40 in Sheffield) with type 1 diabetes will be recruited, with suitable volunteers being asked to participate. Half will be randomly allocated to have the insulin pump treatment and the other half will have the injection treatment, both in combination with a DAFNE course, which provides training in the skills needed for people to manage their diabetes themselves.

    An insulin pump is a device similar in size to a mobile phone that contains sufficient insulin to supply the patient?s needs throughout the day. Although relatively expensive, it has important potential benefits such as better control of blood sugar levels, reduced risk of hypoglycaemia (low blood sugar), a more flexible lifestyle and better quality of life.

    However, until now, it has not been proven how well insulin pump therapy works when compared with injections in patients who are taught effectively to manage their own insulin therapy. It is not known, for example, whether insulin pumps can be more effective because of the quality of the education patients receive, or because of the devices themselves.

    The results of the trial will help to determine whether the NHS should spend money on insulin pumps with education and, if so, how much.

    Researchers are currently looking to recruit suitable patients onto the trial. Patients must be over 18 years of age; have type 1 diabetes; have no preference over the use of pumps or injections; be willing to monitor their blood glucose and assess food intake; and must not currently be using a pump. If you are interested in taking part or finding out more, please contact Professor Simon Heller at s.heller@sheffield.ac.uk or call 0114 271 3204 or Carolin Taylor at carolin.taylor@sth.nhs.uk or 0114 271 4981 .

    Notes to Editors

    1. About the trial: The full title of the trial is REPOSE: The Relative Effectiveness of Pump Therapy Over MDI and Structured Education. The other sites taking part are Kings College Hospital London, Harrogate District Hospital, Addenbrookes Hospital Cambridge, Glasgow Royal Infirmary, Dumfries and Galloway Royal Infirmary and Royal Edinburgh Hospital.

    2. About type 1 diabetes: type 1 diabetes develops when the insulin-producing cells in the body have been destroyed and the body is unable to produce any insulin. It can develop at any age but usually appears before the age of 40, and especially in childhood. It has more than 250,000 sufferers in the UK.

    3. About the Health Technology Assessment Programme (HTA): The HTA programme is part of the National Institute for Health Research (NIHR). It produces independent research information about the effectiveness, costs and broader impact of healthcare treatments and tests for those who plan, provide or receive care in the NHS. For more information visit www.hta.ac.uk



    Released at:
    16:00 26/10/2011
     
  2. Alba37

    Alba37 Approved members

    Joined:
    Oct 20, 2008
    Messages:
    167
    Info meeting to be held on 18th January in Diabetes Scotland offices, Glasgow. Will post more information when I have it.
     

Share This Page

- advertisement -

  1. This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
    By continuing to use this site, you are consenting to our use of cookies.
    Dismiss Notice